[Expression of cyclooxygenase (COX)-2 in astrocytic tumors and anti-tumor effects of selective COX-2 inhibitors].
Cyclooxygenase (COX)-2 of astrocytic tumors was studied by immunohistochemistry. COX-2 was expressed in 8 of 12 (75%) glioblastoma multiforme, 1 of 7 (14%) anaplastic astrocytoma, but none in astrocytoma. COX-2 was detected by an immnoblotting in 2 of 9 human glioblastoma cell lines (KNS42 and U138). In glioblastoma cell lines, NS398 and Etodolac inhibited cell proliferation and induced apoptosis. The result showed that COX-2 expression may be related with histological grades and COX-2 inhibitors will be one of promising therapeutic tools in human astrocytic tumors.
Murakami
Hiromi
H
Oncology Research Center, Hokuto Hospital, ORC, Hokuto Hospital, Kisen 7-5, Inada-cho, Obihiro, Hokkaido 080-0833, Japan.
Sawa
Hiroki
H
Kamada
Hajime
H
D000328:Adult; D000368:Aged; D001254:Astrocytoma / Q000188:drug therapy / Q000201:enzymology*; D051546:Cyclooxygenase 2 / Q000032:analysis*; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D017308:Etodolac / Q000494:pharmacology; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy / Q000201:enzymology; D006801:Humans; D015151:Immunoblotting; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009578:Nitrobenzenes / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D052246:Cyclooxygenase 2 Inhibitors; D009578:Nitrobenzenes; D013449:Sulfonamides; C080955:N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; D017308:Etodolac; D051546:Cyclooxygenase 2